FICCI submits recommendations to government for regulatory reforms in pharma
The recommendations comprise improvement proposals for new drug registrations; animal toxicity and testing, clinical trials; and measures to shape the R&D ecosystem for India pharma sector
The Federation of Indian Chambers of Commerce and Industry (FICCI) has submitted some of its recommendations for regulatory reforms in the pharma sector to high-level government authorities from the Department of Pharma, Ministry of Health & Family Welfare and Niti Aayog. The detailed recommendations cover four major areas: improvement proposals in new drug registrations; animal toxicity and testing; clinical trials, and shaping the R&D ecosystem for Indian pharma sector in terms of infrastructure and capacity building.
S Sridhar, Chairman, FICCI Pharma Committee and MD, Pfizer India said, “We welcome the Government’s initiative to accelerate regulatory reforms in India. FICCI has put together one of the most comprehensive recommendations with contributions from the foremost regulatory experts in Indian and global pharma. These recommendations will help deliver a modern, agile, pro-i